USE OF AGOMELATINE TO OBTAIN MEDICATION AIMED AT TREATING PERIVENTRICULAR LEUKOMALACIA

A living animal body including a human, afflicted with periventricular leukomalacia comprises administering to the living animal body, an amount of agomelatine or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, or its hydrate, crystalline form, or addition salt with acid or base that is effective for tr...

Full description

Saved in:
Bibliographic Details
Main Authors MICHAEL SPEDDING, ELISABETH MOCAER
Format Patent
LanguageEnglish
Portuguese
Published 27.10.2010
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:A living animal body including a human, afflicted with periventricular leukomalacia comprises administering to the living animal body, an amount of agomelatine or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, or its hydrate, crystalline form, or addition salt with acid or base that is effective for treatment of periventricular leukomalacia. The agomelatine is in crystalline form II. ACTIVITY : Cerebroprotective; Vasotropic. MECHANISM OF ACTION : Melatoninergic system receptor agonist; 5-HT-2C receptor antagonist.
Bibliography:Application Number: PT20070291392T